The estimated Net Worth of Alexander L Johnson is at least $10.6 Миллион dollars as of 20 August 2024. Mr Johnson owns over 61,023 units of Caredx Inc stock worth over $8,745,586 and over the last 3 years he sold CDNA stock worth over $1,148,450. In addition, he makes $716,542 as Pres of Patient and Testing Services at Caredx Inc.
Mr has made over 2 trades of the Caredx Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 61,023 units of CDNA stock worth $1,432,820 on 20 August 2024.
The largest trade he's ever made was exercising 61,023 units of Caredx Inc stock on 20 August 2024 worth over $1,432,820. On average, Mr trades about 3,969 units every 0 days since 2021. As of 20 August 2024 he still owns at least 306,540 units of Caredx Inc stock.
You can see the complete history of Mr Johnson stock trades at the bottom of the page.
Alexander L. Johnson is the Pres of Patient and Testing Services at Caredx Inc.
As the Pres of Patient and Testing Services of Caredx Inc, the total compensation of Mr Johnson at Caredx Inc is $716,542. There are 5 executives at Caredx Inc getting paid more, with Peter Maag having the highest compensation of $8,855,740.
Mr Johnson is 47, he's been the Pres of Patient and Testing Services of Caredx Inc since . There are 11 older and 5 younger executives at Caredx Inc. The oldest executive at Caredx Inc is Ralph Snyderman, 80, who is the Independent Director.
Alexander's mailing address filed with the SEC is C/O CAREDX, INC., 8000 MARINA BOULEVARD, BRISBANE, CA, 94005.
Over the last 10 years, insiders at Caredx Inc have traded over $60,271,359 worth of Caredx Inc stock and bought 1,726,634 units worth $9,072,700 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Neil Gagnon и Peter Maag. On average, Caredx Inc executives and independent directors trade stock every 17 days with the average trade being worth of $615,506. The most recent stock trade was executed by Alexander L Johnson on 20 August 2024, trading 61,023 units of CDNA stock currently worth $1,432,820.
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
Caredx Inc executives and other stock owners filed with the SEC include: